She also referenced recent portfolio actions, including the acquisition of SpringWorks and the divestment of Surface Solutions, as well as a “string of pearls” approach to technology additions such as Mirus Bio, UnitySC, and a chromatography business acquired from GSR late last year.Garijo reiterated that Merck operates across three businesses—Healthcare, Life Science, and Electronics—while concentrating investment on the three growth pillars. In Life Science, she highlighted bioprocessing leadership within ...

Merck (OTCPK:MKGA.F) FY Conference January 12, 2026 02:15 PM ET Speaker0to the 44th J.P. Morgan Healthcare Conference. I'm Richard Vosser, European Pharma Analyst with J.P. Morgan. It's my great pleasure to host and introduce the CEO, Belén Garijo, from Merck KGaA, Darmstadt, Germany, and their presentation today at the conference. Just before I hand over to Belén, just a few housekeeping remarks. If you want to ask a question, put your hand up and we can take it in the room, or you can put your questions o ...

Market Reactions to Trade Policies - In early October 2025, President Trump's threat of "massive" new tariffs on Chinese goods led to significant market declines, with the S&P 500 dropping 2.71%, the Dow Jones Industrial Average down 1.90%, and the Nasdaq 100 falling 3.49% [2] - A subsequent post on Truth Social by Trump on October 13 reassured investors, resulting in a market rebound where the Dow surged over 500 points, the S&P 500 gained 1.24%, and the Nasdaq climbed 1.54% [3] - On October 17, Trump's comments about tariffs being "not sustainable" and a meeting with Chinese President Xi Jinping prompted a modest rebound in U.S. stock indices, with the Dow advancing 0.2% and the Nasdaq recovering from earlier losses [4] Pharmaceutical Industry Developments - President Trump announced a deal with Merck KGaA on October 17 to reduce the prices of IVF drugs by 84%, which is expected to save families around $2,200 per IVF cycle, while also providing Merck with tariff reprieves and expedited drug reviews [5] - Conversely, Trump's announcement regarding the potential price drop of the weight-loss drug Ozempic to $150 from around $1,000 led to a sharp decline in shares for Novo Nordisk, which fell as much as 6%, and similar declines for Eli Lilly and other competitors [6][7] - Analysts expressed skepticism about Trump's price target for Ozempic, labeling it as "aggressive posturing" and noting that insured patients already pay significantly less [8] Impact of Social Media on Market Sentiment - Trump's posts on Truth Social have become a barometer of market sentiment, with the stock of Digital World Acquisition Corp. (DWAC) experiencing a 67.18% decline year-to-date, hitting a 52-week low of $7.57 [9] - Despite optimistic forecasts for DWAC, the reality has been a downward trajectory, with predictions of further declines [9] Overall Market Dynamics - The market's reaction to Trump's policies is characterized by rapid fluctuations, with significant drops and rebounds driven by tariff rhetoric and casual comments on drug prices [10] - Investors are in a state of constant alertness, adapting to the unpredictability of Trump's announcements and the resulting market impacts [10]